Infliximab and adalimumab are two of the most important biologic drugs to treat patients suffering from Inflammatory Bowel Diseases (IBD) or Rheumatoid Arthritis (RA). A high percentage of patients taking these TNF-alpha drugs lose drug response over time. This can either be because of suboptimal dosage, shown with trough levels, or because of antibodies the patient develops against the drug. Assays measuring drug levels and antibodies against anti-TNF drugs can identify patients that lose response and thus help physicians optimize treatment.
The Quantum Blue® therapeutic drug monitoring (TDM) product portfolio offers lateral flow tests for rapid measurement of infliximab and adalimumab trough levels in patient serum as well as for measuring anti-drug antibodies against both drugs.
At the virtual AACC 2020 BÜHLMANN had the great opportunity to present two posters about the Quantum Blue® Infliximab.
First successful comparison of Quantum Blue® rapid TDM assay standardization with WHO international standard for infliximab
Since various assays exist to measure infliximab trough levels in patient blood, the WHO introduced a standard for infliximab to improve comparability among different tests. An excellent correlation of the Quantum Blue® Infliximab rapid test with the WHO international standard for infliximab (NIBSC 16/170) was found. Thus, the rapid test Quantum Blue® Infliximab is shown to be standardized according to WHO standards.
Quantum Blue® Infliximab highly correlates to the HPLC tandem mass spectrometry method at Mayo Clinic
The comparability of the Quantum Blue® Infliximab lateral flow test and the highly precise HPLC tandem mass spectrometry (LC-MS/MS) established at the Mayo Clinic was evaluated. The research group at Mayo Clinic proves in this poster that the Quantum Blue® Infliximab rapid test correlates very well with the LC-MS/MS method and offers fast and high quality quantitative result reporting in a near-patient environment.